Cardiff Oncology (CRDF) Stock Price, News & Analysis

Company Overview

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $2.17 to $2.24
• 50-Day Range: $2.21 to $4.45
• 52-Week Range: $2.09 to $5.64
• Volume: 913,730 shs
• Average Volume: 1.43 million shs
• Market Capitalization: $147.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.10
• Consensus Rating: Moderate Buy

Cardiff Oncology Stock Analysis - MarketRank™

Cardiff Oncology scored higher than 34% of companies evaluated by MarketBeat, and ranked 753rd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cardiff Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cardiff Oncology has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cardiff Oncology are expected to grow in the coming year, from ($0.99) to ($0.94) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cardiff Oncology is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cardiff Oncology is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cardiff Oncology has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

30.68% of the float of Cardiff Oncology has been sold short.

Short Interest Ratio / Days to Cover

Cardiff Oncology has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Cardiff Oncology has recently decreased by 0.32%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardiff Oncology does not currently pay a dividend.

Dividend Growth

Cardiff Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

30.68% of the float of Cardiff Oncology has been sold short.

Short Interest Ratio / Days to Cover

Cardiff Oncology has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Cardiff Oncology has recently decreased by 0.32%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

6 people have searched for CRDF on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.

MarketBeat Follows

2 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Cardiff Oncology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $710,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 7.70% of the stock of Cardiff Oncology is held by insiders.

Percentage Held by Institutions

Only 16.29% of the stock of Cardiff Oncology is held by institutions.

CRDF Stock Analysis - Frequently Asked Questions

How have CRDF shares performed this year?

Cardiff Oncology's stock was trading at $4.34 on January 1st, 2025. Since then, CRDF stock has decreased by 49.1% and is now trading at $2.21.

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:CRDF) released its quarterly earnings results on Tuesday, July, 29th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02. The business earned $0.12 million during the quarter, compared to analysts' expectations of $0.11 million. Cardiff Oncology had a negative trailing twelve-month return on equity of 77.94% and a negative net margin of 9,344.14%.

Who are Cardiff Oncology's major shareholders?

Cardiff Oncology's top institutional shareholders include Blair William & Co. IL (3.79%), Geode Capital Management LLC (2.25%), Adage Capital Partners GP L.L.C. (2.14%) and Acorn Capital Advisors LLC (2.12%). Insiders that own company stock include Gary W Pace, Lale White, James E Levine and Mark Erlander.
View institutional ownership trends.

How do I buy shares of Cardiff Oncology?

Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Digital Turbine (APPS), Meta Platforms (META) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 8/26/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRDF
• CIK: 1213037
• Web: cardiffoncology.com
• Phone: (858) 952-7570
• Fax: N/A
• Employees: 20
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Cardiff Oncology: $10.10
• High Price Target: $19.00
• Low Price Target: $3.50
• Potential Upside/Downside: +362.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.43 million
• Net Margins: -9,344.14%
• Pretax Margin: -9,344.14%
• Return on Equity: -77.94%
• Return on Assets: -63.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.42
• Quick Ratio: 4.42

Sales & Book Value

• Annual Sales: $545 thousand
• Price / Sales: 266.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.86 per share
• Price / Book: 1.17

Miscellaneous

• Outstanding Shares: 66,526,000
• Free Float: 61,403,000
• Market Cap: $145.36 million
• Optionable: Optionable
• Beta: 1.54